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Background. One-third of Crohn’s disease (CD) patients present perianal fistula. The gold standard in the diagnosis and
treatment of symptomatic perianal disease (PAD) in CD is the exploration of the anal canal and distal rectum under
anesthesia (EUA). This procedure is mainly conducted as a day case surgery. Unfortunately, it is not always possible to
proceed within the ideal timing and any delay may well represent a relevant clinical issue. The aim of this study was to
evaluate the feasibility of outpatient treatment of symptomatic perianal fistulas in CD patients. Methods. All CD patients
under regular follow-up at our inflammatory bowel disease referral center, presenting with symptomatic perianal fistulas,
were offered surgical consultation. The data of patients were prospectively collected for three years (February 2014 to
February 2017) for the purpose of the study. All clinical information, including previous EUA and/or records from MRI
and endoscopic ultrasound, was included. Outpatient anal canal and distal rectum exploration and treatment (OE) were
undertaken during the specialist surgical consultation. Fistulas were classified according to Parks’s classification; the type
of outpatient treatment and compliance of patients were recorded. Pain was assessed by VAS at the time of the
procedure and during the first control. Patients were followed up in the surgical clinic in relation to the study. Results.
Ninety-two CD patients with symptomatic perianal fistulas had surgical consultation during the study period. OE was
offered to all but 18 patients who fulfilled the exclusion criteria or had an extremely severe disease; six patients refused
the OE (8.11%). Of the 68 patients undergoing OE, eleven (16.18%) had previous surgery for perianal disease. The OE
was accomplished in sixty-one patients (89.71%), while in 7 patients, it was abandoned for scarce compliance. Nine
patients (14.75%) underwent drainage of perianal abscess; in 3 of them, it was possible to probe the fistula tract, find
the internal orifice, and pass a loose seton. Overall, setonage was performed in 50 patients (81.97%). Rectovaginal setons
were placed in 3 patients and more than one seton (up to 3) in 6 cases. Fistulotomy was performed in 4 simple
subcutaneous fistulous tracts. Concordance with the preoperative findings was found in 54 out of 61 patients. EUA was
scheduled at the time of OE for the 7 patients who did not complete the procedure. All sixty-one patients who had the
OE were followed up for a minimum of 12 months. Conclusions. This preliminary study indicates that OE in CD
patients with symptomatic perianal fistulas is safe and feasible in a high-volume referral center. It might provide several
benefits, including patients’ logistics, reduce or remove patients’ symptoms and discomfort, allow for a timely start of
medical therapy, and avoid further complications.
1. Introduction
One-third of Crohn’s disease (CD) patients have perianal
disease [1–3]. The gold standard to assess symptomatic
perianal disease (PAD) in CD patients is the exploration of
the anal canal and distal rectum under anesthesia (EUA)
[4–7]. EUA usually allows a correct diagnosis of fistulous
tracts, a classification of the fistula, and an appropriate
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treatment of the PAD at the same time. The aim of the surgi-
cal therapy is to control sepsis, preserving anorectal functions
and avoiding further complications.
The aim of this preliminary study was to assess the feasi-
bility of an outpatient examination (OE) and treatment in a
nonselected population of CD patients with symptomatic
perianal fistulas.
2. Methods
During the study period, all the patients on regular follow-up
at our referral center for inflammatory bowel disease (IBD),
presenting with symptomatic perianal fistulas, were enrolled
in this study of feasibility. There were no general exclusion
criteria, but minor legal age. Patients with a known horse-
shoe fistula, recorded incontinence, multiple external orifices,
substantial discharge, marked discomfort or limitation, and
substantial induration or large abscesses were excluded. To
assess the severity of the condition, the Perianal Disease
Activity Index (PDAI) was used [8]. Furthermore, noncom-
pliant patients or patients with major comorbidities were also
excluded. Diagnosis of CD was made according to the
conventional clinical, endoscopic, histological, and radiolog-
ical criteria. A dedicated gastroenterologist and surgeon
evaluated all patients. Magnetic resonance imaging (MRI)
and/or endoscopic ultrasound examination were performed
whenever possible prior to the multidisciplinary consulta-
tion. Data regarding demographics and preoperative clinics
(including duration of the disease, localization and behavior
of CD, previous surgery, comorbidities, current therapy,
and radiological or endoscopic assessment of perianal
fistulas) were reviewed focusing on the results of previous
imaging and surgical reports.
The need for the EUA was explained, and the OE was
offered alternatively and, upon a patient’s acceptance, done
within 48-60 hrs. Informed consent was obtained from all
patients. No ethics committee agreement was requested.
The OE was conducted with the patient on a left lateral posi-
tion (same as for any anorectal inspection) always by the
same surgeon with the aid of a dedicated specialist nurse. A
careful assessment of the perianal region was undertaken in
search for lumps, discharge, or orifices. A 9mm-in-length
lighted surgical proctoscope was used to evaluate the anal
canal and distal rectum. Small-to-medium size abscesses
were drained after local injection of lidocaine 2%+naropine
7.5%. Electrocautery was rarely used to obtain hemostasis,
but gentle package with soaked sponges. The external orifice
or the abscess cavity was injected with hydrogen peroxide
(H2O2) or a saline solution, to find the internal orifice; an
olive-tip malleable metal wire was used to probe the sinus
tract. The classification proposed by Parks in 1976 [9] was
used for a fistula-type recording. Usually, whenever the inter-
nal orifice was found, a loose silicon seton (vessel loop) was
placed and secured with a double-silk tie. Occasionally,
simple posterior fistulas were treated with open fistulotomy
or by means of cutting setons.
In order to assess the feasibility of the outpatient proce-
dure, the following parameters were taken into account.
Discomfort or pain was evaluated at the end of the procedure
(perioperative pain/discomfort) and after one week, using the
Visual Analogical Score (VAS) [10]. The time to discharge
(ranging from minutes to hours after the procedure), the
need for pain killer therapy, recurrence at one year, and the
incidence of anal incontinence were recorded data. In
patients who had a cutting seton placed, a weekly outpatient
control was scheduled until the fistulotomy was completed.
In case of treatment not performed or considered incomplete
(i.e., abscess drainage but fistulous tract not found), a day
surgery EUA was scheduled and the case was recorded as
treatment failure. The data were collected on a Microsoft®
Excel spreadsheet, and the results were compared with those
available in literature in order to establish if OE may be con-
sidered a safe and effective procedure. The evaluation of the
late postoperative discomfort and patients’ satisfaction was
performed by means of a telephone interview.
3. Results
Ninety-two consecutive patients with evidence of symptom-
atic perianal fistulas were seen by our IBD referral center
from February 2014 to February 2017. Eighteen patients
did not fulfill the inclusion criteria and were excluded from
the study: two had horse-shoe fistulas, nine had a PDAI > 3
concerning the number of fistulas, discomfort or pain, and
substantial induration or large abscesses, one patient was
excluded because of minor legal age, four were excluded
because of known incontinence, and two were excluded
because they had taken double antiaggregant therapy for car-
diac stenting. Compliance was good, as only six patients
refused the proposed procedure (8.11%). Of the 68 patients
undergoing OE, eleven (16.18%) had already undergone sur-
gery for perianal disease in the past. OE was not completed in
seven patients mostly due to discomfort or anxiety during the
procedure. In 61 patients (89.71%), it was possible to com-
plete the outpatient exploration of the anal canal and distal
rectum to assess the PAD. A surgical treatment was done in
60 of them. No painkillers were given before or just after
the procedure.
The patients’ characteristics are summarized in Table 1.
The findings in accordance with Parks’s classification and
surgical treatment are shown in Table 2. Hughes classifica-
tion is also reported for the purpose of the study [11].
Nine patients (14.75%) underwent drainage of perianal
abscess; in 3 of them, it was possible to probe the fistula
tract, find the internal orifice, and pass a loose seton.
Overall, setonage was performed in 50 patients (81.97%).
More than one seton (up to 3) was passed in 6 cases. Fistulot-
omy was performed in four simple low posterior anorectal
sinuses with no involvement or a very subtle involvement
of the internal sphincter. In the other ten extrasphincteric
fistulas, it was preferred to pass a loose seton, giving the pres-
ence of a degree 2-3 discharge (PDAI) or in the presence of a
localization in the upper quadrants of the anus. Seven
patients subsequently had a cutting seton fistulotomy. Three
patients with rectovaginal fistulas had a loose seton through
the vaginal orifice. In four cases of very low posterior trans-
sphincteric fistula, fistulotomy was achieved by means of a
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cutting seton. Concordance with the preoperative findings
was found in 54 out of 61 patients (88.52%).
The pain evaluation score showed a median VAS of 2.0
(range 0-4) immediately after the procedure (perioperative)
and a median score of 1.0 (range 0-2) a week later.
No complications were recorded during or after the
procedures.
Patients left the outpatient department from few minutes
to two hours after the procedure with paracetamol (up to 3
grams per day) prescribed for the first 3 days in case of pain.
The first control was scheduled in one week or after 3
days for those patients who had abscess drainage.
All the patients were followed up for a minimum of 12
months. In 39 patients, data from a 24-month follow-up were
recorded.
During the FU period, 7 patients (12%) had PAD relapse
(requiring intervention):
(i) Two patients with extrasphincteric fistulas: the first,
who had a simple setonage because of severe procti-
tis, showed a rectovaginal orifice at 8 months (it was
in fact a relapse of a previously treated rectovaginal
fistula) and underwent EUA and setonage. In the
other patient, who had a fistulotomy during the
OE, a redo fistulotomy with conization under narco-
sis was performed to avoid sepsis
(ii) Two cases of suprasphincteric fistula: one patient
develops an abscess 5 months from seton placement,
came to the emergency department, and had surgical
drainage and further setonage under narcosis. The
second patient that also had a simple setonage dur-
ing the OE was hospitalized after 11 months because
of severe proctitis, cellulitis, and perineal pain; he
underwent EUA, partial fistulectomy, and setonage
of a horse-shoe fistula
(iii) In three cases (2 intersphincteric and 1 transsphinc-
teric), it was possible to repeat the outpatient explo-
ration to treat the recurrence and a setonage of a
different sinus tract was performed
Furthermore, both the patients with rectovaginal fistulas
eventually had in-hospital surgery: in 1 case, a rectal
advancement flap was performed, while fistulectomy, repair
of the vagina, and a setonage of an adjacent perianal fistula
were carried out in the second patient.
At the telephone interview, 57 (95%) patients were
highly satisfied of the received treatment, scoring 9 of 10
in a scale 0-10.
4. Discussion
Almost one-third of CD patients show symptoms of PAD
[10, 12]. The risk of developing PAD is consistent with the
time from the diagnosis of CD, 20% after ten years and up
to 30% after twenty years. However, PAD is far more com-
mon in patients with colon (41%) and rectum (90%) localiza-
tion and less in patients with ileal disease (12%). [13, 14].
Early diagnosis and correct treatment are crucial to allow
patients to promptly start medical treatments with antitu-
mor necrosis factor (tnf) which is considered the corner-
stone of treatment, offering the best long-term control of
PAD [15, 16]. The diagnosis and treatment may be delayed
since the clinical pathway for this subset of patients is still
not fully standardized, even in specialized centers. Recently,
a delay in many elements of the clinical pathway in patients
with Crohn’s anal fistula has been reported [15], and it was
seen that the commencement of the anti-tnf therapy could
be as long as one year. Resolving the delay is also important
to reduce the debility associated with PAD.
Perianal fistulas in CDmay be simple or complex accord-
ing to the American Gastroenterological Association (AGA)
[17–20]. Simple fistulas have a high healing rate, while com-
plex fistulas are difficult to treat and show a poor healing rate
and increased rate of relapse. The proper surgical choice
depends on the anatomy, the type of fistula, and finally, the
surgeon’s expertise [21–25]. Active proctitis control must
be achieved whenever possible prior to any surgical treat-
ment. Treatment strategy and procedures are different in an
acute or in an elective setting; in acute management, the main
aim is sepsis control: incision and drainage of every abscess
are strongly advised, while placement of a loose seton should
be considered only if the fistulous tract can be promptly and
easily identified [7]. In an elective setting, an exploration of
the anal canal and distal rectum under anesthesia is recom-
mended and, in case of complex fistula, even in the presence
of proctitis, a loose, draining seton could be passed if the
internal and external orifices of the fistulous tract are found.
A fistulotomy or fistulectomy can be safely considered for
simple posterior fistulas [26].
Several operations have been deployed to treat complex
perianal fistulas in Crohn’s disease. The fistulous tract can
Table 1: Patients’ characteristics.
Characteristics
Sex ratio (M : F) 35 : 26
Age (median, years) 32.8 (18-56)
Duration of perianal disease:
median (months)
17 (0-68)
Localization of CD (%)
Distal ileum and ascending
colon (65%)
Left colon/rectum (24%)
Other localizations (11%)
Current therapy
Antibiotics +/- other
medications: 30 (49.18%)
Steroids only: 16 (26.23%)
5-ASA: 2 (3.28%)
Thiopurine: 4 (6.56%)
Infliximab or similar: 4 (6.56%)
Previous perianal surgery 11 (16.18%)
Imaging
Yes: 20
MRI: 20 (32.79%)
MRI + US: 5 (8.19%)
No: 41
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be excised, injected with glue, tied and divided, covered with
a mucosal flap, or injected with autologous stem cells. Unfor-
tunately, none of these procedures were capable to show a
clear advantage over the others, especially in Crohn’s disease.
The aim of the surgical treatment of PAD in CD patients
should be symptoms or complication control, allowing
patients to pursue a timely medical therapy, in a multidisci-
plinary management.
In the presence of a symptomatic perianal fistula, an opti-
mal result can be considered to avoid sepsis, allowing for a
good drainage before thinking to the complete healing of
the fistula and finally preventing the recurrence and preserv-
ing the continence of the anal sphincter. It is essential to
ensure timely treatment, because perianal fistulas signifi-
cantly impair the quality of life of the patients, to avoid the
potentially disastrous consequences such as those of an
undrained sepsis or ramification of the fistulous tracts.
Only the patients with symptomatic Crohn’s anal fistula
should undergo a surgical treatment.
The gold standard treatment for symptomatic perianal
disease in CD patients is conducted during the EUA. Most
of the series available in literature refer to day surgery or
overnight admission. Unfortunately, a timely treatment is
not always possible and this, as said, may well represent a rel-
evant clinical issue. Our study was designed to evaluate the
feasibility of outpatient treatment of CD patients with peria-
nal fistula in terms of safety and feasibility. Patient compli-
ance, clinical results, and costs were also evaluated.
The OE was feasible in the vast majority of patients
(74 out of 92, 80.4%), and we had no immediate or
delayed complications due to the procedure. Patients’
compliance for both procedure acceptance and procedure
execution was very high (68 out of 74, 91.9%, and 61
out of 68, 89.7%, respectively).
Twenty-four percent of our patients had colonic or rectal
localization of Crohn’s disease. These data seem to differ
from those of literature (up to 41% in colonic localization
and up to 92% in rectal localization) [22], but these data
referred to active disease, while in our series, only two
patients showed severe active proctitis at OE. It is possible
that there was a different method or judgement and that this
may introduce a bias in the results. Thirty-seven (59.7%)
patients were off therapy at the time of the first perianal
symptoms, while 24 (39.3%) were under treatment with
immunosuppressive or biological therapy.
In this preliminary series, we recorded the surgical
treatment associated with the OE: a total of 50 loose seton
placements, 9 abscess drainages, and 4 fistulotomies were
performed in 68 patients.
We reported a relatively high rate of seton placement,
even in the more difficult fistula types, up to 67% in supras-
phincteric fistulas and up to 71% in extrasphincteric ones.
According to the Association of Coloproctology of Great
Britain and Ireland consensus conference on surgical
management of fistulating perianal Crohn’s disease, experi-
enced surgeons should always try to place a seton when the
fistulous tract is readily identifiable (evidence level 1A) and
this should be possible most of the times in “skilled hands”
[7]. Moreover, in this series, more than 50% of patients with
extrasphincteric or suprasphincteric fistulas had been studied
by means of MRI before the OE.
Seven patients relapse one year after the OE (10.9%).
Nonetheless, those are not real relapses, considering that
the aim of the treatment was not the healing of the fistu-
lous tract. However, it was necessary to take these patients
back to undergo a subsequent operation. No alternative
treatment to obturate the fistulous tract was proposed in
the two-year study period. We believe that stem cell ther-
apy according to the ADMIRE-CD trial [27] can be
proposed in the outpatient setting.
In this series, OE seems feasible with good results at one
year. Compliance of patients to the procedure was high and,
from a surgical point of view, the OE was nice to perform
without difficulties or trouble in all cases. In this series, there
was never a case in which the surgeon felt to be in a difficult
situation. The OE was abandoned only in few cases, mostly of
high transsphincteric or suprasphincteric fistulas, due to the
patients’ discomfort. Horse-shoe fistulas do represent a limit
to OE.
The aim of the OE was anal canal exploration and surgi-
cal control of patients’ symptoms and prevention of further
complications related to Crohn’s perianal fistulas.
We believe that OE could be an efficacious answer to
the issues recently underlined by Lee et al. [15] and those
reported above. OE can be a part of a clinical pathway for
patients with perianal Crohn’s fistulas. It is perceived by
patients as less invasive and allows for timely commence-
ment of anti-tnf therapy. This is, in the authors’ opinion,
[3] the best clinical scenario, since Crohn’s disease is a
systemic degenerative chronic condition in which the peri-
anal disease represents only a local, although troublesome,
occurrence for some patients. A less invasive procedure,
capable of minimizing distress and discomfort for patients
often deemed to several major and minor surgical proce-
dures during their life and in whom a timely medical
treatment, is crucial.
This procedure should be offered in a high-volume center
in which a multidisciplinary dedicated team is available. In
selected cases, OE may be offered as a “bridge to surgery,”
able to faster solve critical clinical issues or palliate disabling
symptoms with low morbidity and discomfort, also allowing
patients to continue medical therapy. OE can be repeated, if
necessary, in different occasion. From an economical point
of view, the OE can definitively save logistics and money.
This can also represent a relevant point in favour of the
OE, considering that, as reported by a Spanish survey, the
yearly costs of CD patients for the national health system
account for 8.289 euros per patient and that 12.4% of this
goes for surgical treatment [28].
The OE surely is a minimally invasive approach, with low
morbidity and very low patient stress. It is the authors’ opin-
ion that the key success of the OE is the relationship of the
patients with the referral IBD center. In this series, all the
patients were known to the center and the multidisciplinary
consultation plays a great role for increasing patients’ com-
pliance. Our study suggests that OE could be a safe and effec-
tive procedure that can be proposed to the vast majority of
patients with Crohn’s fistulas. It is not recommended in
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nonexperienced hands and in high complex or rectovaginal
fistulas (Hughes classification 1b, 1d or 2d, and 2e). OE could
be compared to EUA to assess the perceived advantages of
this preliminary case series.
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